Karunanidhi Santhana LAKSHMI, Shrinivas SHARMA

Potential of Allylmercaptocaptopril as an Anti Cataract Agent against Galactosemic Cataract in Rats An in Vitro and in Vivo Studies

Amaç: Alilmerkaptokaptopril(AMC), deney hayvanlarında, selenit ile indüklenmiş katarakta karşı anti katarakt aktivivasyona sahip olduğu gösterilen Kaptopril ve Allisinin kovalent bağlanmasının ürünüdür. Bu çalışmada AMC ‘nin galaktazomik katarakt da antikatarakt potansiyelinin biyokimyasal mekanizmasını aydınlatmak amaçlandı. Metod: AMC ‘nin koruyucu etkisi invivo ve invitro olarak ratlarda galaktoz ile indüklenmiş katarakt da değerlendirildi ve kaptoprilin etkisi ile karşılaştırıldı. AMC ve Kaptoprilin galaktozemik katarakt da kataraktın başlangıcı ve olgunlaşması üzerine olan etkisini incelendik. Bulgular: AMC, galaktoz ve kaptopril ile tedavi edilen lenslerle karşılaştırıldığında rat lenslerinde ki galaktoz ile indüklenen osmotik stresin belirteci olan polivol düzeyini azalttı. Galaktoz verilen grupta normal lensler ile karşılaştırıldığında Glucose- 6-phosphate dehidrogenaz, suksinat dehidrogenaz, laktat dehidrogenaz aktivitesi ve indirgenmiş gulutatyon düzeyleri azaldı. İkinci olarak, çalışmanın in vivo aşamasında AMC tedavisi, kaptopril tedavisi ile karşılaştırıldığında galaktoz verilen sıçanlarda kataraktın başlangıcı ve olgunlaşması önemli derecede geciktirdi. Sonuç: Bu sonuçlar galaktozın indüklediği kataraktı AMC nin dengelediği görüşünü desteklemektedir. AMC nin anti katarakt etkisi lens enzimlerinin etkisini koruma ve yerine getirme gücü ve glutatyon kaynağı olmasından dolayıdır.

Ratlarda galaktazomik katarakta karşı alilmerkaptokaptopril’in anti katarakt ajan olma potansiyeli

Aim: Allylmercaptocaptopril (AMC) is a covalently bonded product of allicin and captopril has been evaluated for its anticataract activity against selenite induced cataract in experimental animals. We wanted to evaluate its anticataract potential in galactosemic cataract to elucidate biochemical mechanism to appraise its activity. Method: We examined the protective effect of AMC in both in vitro and in vivo models of galactose-induced cataract in rats and compared the effect with captopril. We evaluated the effect of both captopril and AMC on onset and maturation of cataract in galactosemic cataract. Result: AMC reduced the rat lens polyol level, the marker of osmotic stress induced by galactose when compared with galactose treated and captopril treated lens. Glucose-6-phosphate dehydrogenase, succinate dehydrogenase, lactate dehydrogenase activity and reduced glutathione level were decreased in the galactose treated group compared with normal lenses. AMC treatment significantly restored these biochemical levels compared with the galactose treated group. The second, in vivo phase of the study revealed that AMC treatment significantly delayed the onset and maturation of cataract in galactose treated rats compared to captopril treatment. Conclusion: These results support the view that AMC counteracts the effects of galactose in inducing cataract. The anticataract effects of AMC may be related to its intrinsic ability to protect and restore the activities of lens enzymes and the bioavailability of glutathione respectively.

PDF

___

1. Thylefors B. Prevention of blindness: WHO’s mission for vision. World Health Forum 1998;19:53-59.
2. Brian G, Taylor H. Cataract blindness: Challenges for the 21st century. Bull World Health Organ 2001;79:249-56.
3. Harding J. Cataract: biochemistry, epidemiology and pharmacology. 1st ed. London: Chapman & Hall; 1991.
4. Ughade SN, Zodpey SP, Khanolkar VA. Risk factors for cataract: a case control study. Indian J Ophthalmol 1998;46:221-7.
5. Spector A. The lens and oxidative stress. In: Seis H, editor. Oxidative stress: oxidants and antioxidants. London: Academic Press;1991. p. 529-58.
6. Varma SD, Devamanoharan PS, Morris SM. Prevention of cataracts by nutritional and metabolic antioxidants. Crit Rev Food Sci Nutr 1995;35:111-29.
7. Bhat K. Scavenging of peroxide and related oxidants in human brunecent cataracts. In: Gupta SK, editor. Ocular pharmacology: recent advances. New Delhi, India: Indian Ocular Pharmacological Society; 1991. p. 32-8.
8. Jacques PF, Chylack LT Jr. Epidemiological evidence of a role for the antioxidant vitamins and carotenoids in cataract prevention. Am J Clin Nutr 1991;53:352S-5S.
9. Govantes C, Marin J. Effect of angiotensin-converting enzyme inhibitors on quality of life in hypertensive patients: pharmacodynamic basis. Fundam Clin Pharmacol 1996;10:400–05.
10. Richer C, Giroux B, Plouin PF, Maarek B, Giudicelli JF. Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. Br J Clin Pharmacol 1984;17:243-50.
11. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin converting enzyme: New class of orally active antihypertensive agents. Science 1977;196:441-44.
12. Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN. Interruption of the rennin angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1979;1:274-80.
13. Al-Sereiti MR, Turner P. Effect of captopril (an angiotensin- converting enzyme inhibitor) on intraocular pressure in healthy human volunteers. J Ocular Pharmacol 1989;5:1-5.
14. Vogh BP, Godma DR. Effect of inhibition of angiotensin converting enzyme and carbonic anhydrase on fluid production by ciliary process, choroid plexus, and pancreas. J. Ocular Pharmacol 1989;5:303-11.
15. Douglas WW. Polypeptides-angiotensin, plasma kinins and others. In: Gilman A G, Goodman LS, Rail TW, Murad Feds. The pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company 1985;7:639-59.
16. Heel RC, Brogden RN, Speight TM, Avery GS. Captopril: A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 1980;20:409-52.
17. Bagchi D, Prasad R, Das DK. Direct scavenging of free radicals by captopril, an angiotensin converting enzyme inhibitor. Biochem Biophys Res Commun 1989;158:52-7.
18. Chopra M, Scott N, McMurray J, McLay J, Bridges A, Smith WE, Belch JJF. Captopril: A free radical scavenger. Br J Clin Pharmacol 1989;27:396-99.
19. Chopra M, McMurray J, Stewart J, Dargie HJ, Smith WE. Free radical scavenging: A potentially beneficial action of thiol-containing angiotensin converting enzyme inhibitors. Biochem Soc Transactions1990;18:1184-85.
20. Bhuyan KC, Bhuyan DK, Santos O, Podos SM. Antioxidant and anticataractogenic effects of topical captopril in diquat induced cataract in rabbits. Free Radic Biol Med 1992;12:251-61.
21. Follansbee MH, Beyer KH, Vesell ES. Studies on pyrazinoylguanidine: prevention of cataract in STZ-diabetic rats. Pharmacol 1997;54:256-260.
22. Lakshmi KS, Sharma S, Rajesh T, et al. Captopril ameliorates sodium selenite induced cataractogenesis in rats: An in vitro and in vivo study. Pharmacologyonline. 2009;2:1205-15.
23. Naga Raju T, Kanth Rajani V, Lavanya K. Effect of methanolic extract of Allium sativum (AS) in delaying cataract in STZ-induced diabetic rats. j ocul biol dis inform 2008;1(1):46-54.
24. Chitra V, Sharma S. Aparna Lakshmi I. Anticarcinogenic activity of allylmercaptocaptopril against aflatoxin b1 induced liver carcinoma in rats. Eur J Gen Med, Article in press.
25. West CD, Rapoport S. Colorimetric method for the estimation of dulcitol. Proc Soc Exp Biol 1949;70,142-45.
26. Lohr GW, Waller HD. Determination of Glucose-6- phosphate dehydrogenase. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. New York: Academic Press; 1965. p 744-51.
27. Beatly CM, Basinger GM, Dully CS, Bocek RM. Comparison of red and white voluntary skeletal muscles of several species of primates. J Histochem Cytochem 1966;14:590- 600.
28. Bergmeyer HU, Berht E, Hess B. Determination of lactic dehydrogenase. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. New York: Academic Press;1965. p 736-43.
29. Sedlak J, Lindsay RH. Estimation of total, protein-bound and non-protein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968;25:192-205.
30. Reeves PG. Components of the AIN-93 diets as improvements in the AIN-76A diet. J Nutr 1997;127:838S-41S.
31. Sippel TO. Changes in the water, protein, and glutathione contents of the lens in the course of galactose cataract development in rats. Invest Opthalmol 1966;5:568-75.
32. Spector A. Oxidative stress induced cataract: mechanism of action. FASEB J.1995; 9:1173-82.
33. Kinoshita JH. Cataracts in galactosemia: The Jonas S. Friedenwald Memorial Lecture. Invest Ophthalmol 1965;4:786-99.
34. Van Heyningen R. Formation of polyols by the lens of the rat with sugar cataract. Nature 1959;184:194.
35. Van Heyningen R. Metabolism of xylose by the lens. 2. Rat lens in vivo and in vitro. Biochem J 1959;73:197-07.
36. Hockwin O, Ohrloff C. Ageing of lens metabolism. Ophthalmic Res 1979;11:389-07.
37. Hockwin O, Korte I. In Nordmann J, Dardanne MU, editors. Biochemistry of the Eye. Basel: S. Karger; 1968. p 216-21.
38. Van Heyningen R. Galactose cataract: A review. Exp Eye Res. 1971;11:415-28.
39. Rawal UM, Rao GM. Enzymatic studies on the galactose exposed lens. Ind J ophthalmol 1980;28;5-7.
40. Iwig M, Glasser D, Hieka H. Reactivation of nucleus containing lens fibre cells to mitotic growth biochemical and immunochemical analysis. Cell Differ 1978;7:159-69.
41. Iwig M, Glasser D. Investigations on mitotic activity, cell density, and enzyme activities in the bovine eye during cell differentiation. Ophthalmic Res 1972;4:328-42.
42. Reddy VN. Metabolism of Glutathione in the lens. Exp Eye Res 1971;11:310-28.
43. Magaw JM. Glutathione and ocular photobiology. Curr Eye Res 1984;3:83-87.